Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoblituzumab + Pembrolizumab in Advanced Solid Tumors
NCT05338580Phase 2Withdrawn
- Sponsor
- TJ Biopharma
- Start
- Dec 2023
- Primary completion
- Dec 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of enoblituzumab in non-small cell lung cancer (NSCLC), urothelial carcinoma (UC), melanoma, sponsored by TJ Biopharma. Planned start Dec 2023; status: withdrawn.
02
Drugs
enoblituzumab
03
Conditions
non-small cell lung cancer (NSCLC)urothelial carcinoma (UC)melanoma
Beyond the preview
Go deeper on NCT05338580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05338580.